生物制药公司Iovance Biotherapeutics, Inc.（股票代码：IOVA）今日盘前股价暴跌28.03%，引发市场广泛关注。这一大幅下跌主要源于公司公布的第二季度财报不及预期，以及宣布的裁员计划。
根据公司发布的财报显示，Iovance第二季度营收为6000万美元，低于分析师平均预期的6979万美元。同时，公司第二季度每股亏损33美分，也高于分析师预期的28美分亏损。这些数据反映出公司当前面临的经营压力。此外，Iovance还宣布将在今年第三季度前裁员19%，这一举措可能是为了控制成本，但也引发了投资者对公司未来发展的担忧。
尽管面临当前困境，Iovance仍然重申了其全年产品总收入指导范围为2.5亿至3亿美元，而分析师平均预期为3.0018亿美元。然而，投资者似乎对公司的前景持谨慎态度。值得注意的是，Iovance股价今年以来已下跌64.3%，反映出市场对该公司长期表现的持续担忧。这次盘前的大跌进一步加剧了投资者的忧虑情绪，公司未来发展前景仍不明朗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.